Zymo Research and Stori entered a collaboration to commercialize an at-home cfDNA-based early pregnancy test built on Zymo’s sample preservation and cfDNA extraction chemistries. The test is designed to detect placental DNA as early as five weeks of gestation using maternal capillary blood collected at home, then shipped to a CLIA lab for subsequent PCR testing. Zymo and Stori said they completed preliminary analytical validation and are running clinical studies to characterize assay performance. The initial intended applications include prenatal biological sex determination, with the companies positioning the platform as enabling access to sensitive circulating DNA analysis earlier in pregnancy. For the market, the partnership is an example of how enabling technologies in sample prep and computational analysis are moving from laboratory methods into scalable consumer-adjacent workflows.